In the European Union, icosapent<unk>  is indicated to reduce cardiovascular risk as an adjunct to statin therapy. In the United States, icosapent<unk>  is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglyceride levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease. It is also indicated as an adjunct to diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. Intake of large doses (2.0 to 4.0 g/day) of long-chain omega-3 fatty acids as prescription drugs or dietary supplements are generally required to achieve significant (> 15%) lowering of triglycerides, and at those doses the effects can be significant (from 20% to 35% and even up to 45% in individuals with levels greater that 500 mg/dL). It appears that both<unk>  acid (EPA) and docosahexaenoic acid (DHA) lower triglycerides, however, DHA alone appears to raise low-density lipoprotein (the variant which drives atherosclerosis; sometimes very inaccurately called: "bad cholesterol") and LDL-C values (most typically only a calculated estimate and not measured by labs from person's blood sample for technical and cost reasons; however, this is accurately calculated with a less common NMR lipid panel lab), whilst<unk>  acid (EPA) alone does not and instead lowers the parameters aforementioned. Other fish-oil based drugs There are other omega-3 fish-oil based drugs on the market that have similar uses and mechanisms of action: * Omega-3-acid<unk>  esters (brand names Omacor renamed Lovaza in the U.S. to avoid confusion with Amicar and Omtryg), and as of March 2016, four generic versions * Omega-3 carboxylic acids (Epanova); the Epanova brand name was discontinued in the United States. Dietary supplements There are many fish oil dietary supplements on the market. Evidence does not support a beneficial role for ω-3 dietary supplements (as opposed to prescription preparations) to reduce cardiovascular disease as an addition to contemporary medical therapy, including statin therapy. The ingredients of dietary supplements are not as carefully controlled as prescription products and have not been fixed and tested in clinical trials, as prescription drugs have, and the prescription forms are more concentrated, requiring fewer capsules to be taken and increasing the likelihood of compliance.
Ethyl eicosapentaenoic acid
Ellagic acid
Fish oil 
Fish oil
Soybean oil
Etiocholanolone
Conjugated linoleic acid
Retinyl palmitate